EMD Serono Research & Development Institute, Inc.
92
10
21
40
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
33.7%
31 terminated/withdrawn out of 92 trials
56.3%
-30.2% vs industry average
22%
20 trials in Phase 3/4
148%
59 of 40 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (92)
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Role: lead
Met Non Small Cell Cancer Registry (MOMENT)
Role: lead
Anti-GD2 ADC M3554 in Advanced Solid Tumors
Role: lead
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Role: lead
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
Role: lead
First in Human Study of M6223
Role: lead
Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
Role: lead
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Role: lead
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Role: lead
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
Role: lead
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
Role: lead
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Role: lead
First in Human Study of M1069 in Advanced Solid Tumors
Role: lead
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Role: collaborator
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Role: lead
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
Role: lead
Avelumab Program Rollover Study
Role: lead
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
Role: lead
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
Role: lead
A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants
Role: lead